Isatuximab (original) (raw)
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs). Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell leukemia in 2015.
| Property | Value |
|---|---|
| dbo:abstract | Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs). Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell leukemia in 2015. (en) イサツキシマブ（Isatuximab）は、多発性骨髄腫の治療のためのモノクローナル抗体の医薬品である。開発コード：SAR650984。 主な副作用は、好中球減少症、輸液反応、肺炎、上気道感染症、下痢、気管支炎等である。 イサツキシマブは、再発または難治性の多発性骨髄腫の治療を目的とした抗CD38モノクローナル抗体である。2015年に多発性骨髄腫（単剤療法）およびT細胞性白血病を対象とした第II相臨床試験が開始された。 (ja) Изатуксимаб — лекарственный препарат, моноклональное антитело для лечения множественной миеломы. Одобрен для применения: ЕС, США (2020). (ru) |
| dbo:alternativeName | Sarclisa (en) |
| dbo:casNumber | 1461640-62-9 |
| dbo:drugbank | DB14811 |
| dbo:fdaUniiCode | R30772KCU0 |
| dbo:kegg | D11050 |
| dbo:medlinePlus | a620023 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Isatuximab_4CMH.png?width=300 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/isatuximab |
| dbo:wikiPageID | 46661826 (xsd:integer) |
| dbo:wikiPageLength | 31602 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1102295748 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Carfilzomib dbr:Proteasome_inhibitor dbr:Epitope dbr:Amyloidosis dbr:Orphan_drug dbr:Monoclonal_antibody dbr:Multiple_myeloma dbr:Lenalidomide dbr:Shortness_of_breath dbc:Orphan_drugs dbr:Daratumumab dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbc:Monoclonal_antibodies_for_tumors dbr:Dexamethasone dbr:CD38 dbr:Pomalidomide dbr:ImmunoGen dbr:Refractory_disease dbr:Xenotransplantation dbr:United_States_Adopted_Name dbr:Neutropenia dbr:Relapse dbr:Intravenous dbr:Amino-acid dbr:Sanofi-Aventis |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | FC02 (en) |
| dbp:c | 6456 (xsd:integer) |
| dbp:caption | Isatuximab binding CD38 . (en) |
| dbp:casNumber | 1461640 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:class | Antineoplastic (en) |
| dbp:dailymedid | Sarclisa (en) |
| dbp:date | March 2020 (en) |
| dbp:drugbank | DB14811 (en) |
| dbp:h | 9932 (xsd:integer) |
| dbp:kegg | D11050 (en) |
| dbp:legalAu | S4 (en) |
| dbp:legalCa | Rx-only / Schedule D (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:mabType | mab (en) |
| dbp:medlineplus | a620023 (en) |
| dbp:n | 1700 (xsd:integer) |
| dbp:o | 2026 (xsd:integer) |
| dbp:pregnancyAu | C (en) |
| dbp:routesOfAdministration | dbr:Intravenous |
| dbp:s | 44 (xsd:integer) |
| dbp:source | xi/o (en) |
| dbp:synonyms | SAR-650984, isatuximab-irfc (en) |
| dbp:target | dbr:CD38 |
| dbp:tradename | Sarclisa (en) |
| dbp:type | mab (en) |
| dbp:unii | R30772KCU0 (en) |
| dbp:wikiPageUsesTemplate | dbt:Citation_needed dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Update_inline dbt:Use_dmy_dates dbt:When dbt:Fdacite dbt:PDB dbt:Drugs.com dbt:Medcn dbt:ClinicalTrialsGov dbt:Monoclonals_for_tumors |
| dcterms:subject | dbc:Orphan_drugs dbc:Monoclonal_antibodies_for_tumors |
| gold:hypernym | dbr:Antibody |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment | Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis (inflammation of the airways in the lungs). Isatuximab is an anti-CD38 mAb intended to treat relapsed or refractory multiple myeloma. It entered in Phase II trials for multiple myeloma and T-cell leukemia in 2015. (en) イサツキシマブ（Isatuximab）は、多発性骨髄腫の治療のためのモノクローナル抗体の医薬品である。開発コード：SAR650984。 主な副作用は、好中球減少症、輸液反応、肺炎、上気道感染症、下痢、気管支炎等である。 イサツキシマブは、再発または難治性の多発性骨髄腫の治療を目的とした抗CD38モノクローナル抗体である。2015年に多発性骨髄腫（単剤療法）およびT細胞性白血病を対象とした第II相臨床試験が開始された。 (ja) Изатуксимаб — лекарственный препарат, моноклональное антитело для лечения множественной миеломы. Одобрен для применения: ЕС, США (2020). (ru) |
| rdfs:label | Isatuximab (en) イサツキシマブ (ja) Изатуксимаб (ru) |
| owl:sameAs | freebase:Isatuximab yago-res:Isatuximab wikidata:Isatuximab dbpedia-ja:Isatuximab dbpedia-ru:Isatuximab https://global.dbpedia.org/id/y8Vp |
| prov:wasDerivedFrom | wikipedia-en:Isatuximab?oldid=1102295748&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Isatuximab_4CMH.png |
| foaf:isPrimaryTopicOf | wikipedia-en:Isatuximab |
| is dbo:wikiPageRedirects of | dbr:Sarclisa dbr:Isatuximab-irfc |
| is dbo:wikiPageWikiLink of | dbr:Multiple_myeloma dbr:Sarclisa dbr:Daratumumab dbr:ATC_code_L01 dbr:CD38 dbr:ImmunoGen dbr:Selinexor dbr:List_of_therapeutic_monoclonal_antibodies dbr:Isatuximab-irfc |
| is foaf:primaryTopic of | wikipedia-en:Isatuximab |
